Drug Profile
Research programme: selective retinoid X receptor modulators - MaxoCore Pharmaceuticals
Alternative Names: MC-1036; Retinoid X receptor agonists research programme - MaxoCore PharmaceuticalsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MaxoCore Pharmaceuticals
- Class Small molecules
- Mechanism of Action Retinoid X receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Atherosclerosis; Diabetes mellitus; Hypercholesterolaemia; Insulin resistance; Type 2 diabetes mellitus
Highest Development Phases
- No development reported Atherosclerosis; Hypercholesterolaemia; Metabolic syndrome; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypercholesterolaemia in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-syndrome in USA (PO)